Navigating adalimumab biosimilars: an expert opinion

Navigating adalimumab biosimilars: an expert opinion

The patent expiry of Humira in 2018 opened up the current European market to eight adalimumab biosimilars – (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio, Imraldi and Yuflyma – for the treatment of various immune and inflammatory conditions. Amjevita, Hadlima, Hyri...

Full description

Bibliographic Details
Main Authors:	Vered Abitbol, Salim Benkhalifa, Caroline Habauzit, Hubert Marotte
Format:	Article
Language:	English
Published:	Becaris Publishing Limited 2023-10-01
Series:	Journal of Comparative Effectiveness Research
Subjects:	adalimumab biosimilar device dose efficacy formulation nocebo patient expectations patient–physician communication safety

Similar Items

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
by: Luana Colloca, et al.
Published: (2019-11-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)

Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience
by: Martina Maurelli, et al.
Published: (2023-12-01)

Patient state of knowledge on biosimilars – do physicians need to improve education skills?
by: Claudia Cobilinschi, et al.
Published: (2020-06-01)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
by: Ioanna Spanou, et al.
Published: (2019-07-01)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
by: Trinidad Montero-Vilchez, et al.
Published: (2022-02-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023-12-01)

A Budget impact analysis of adalimumab biosimilar: the Italian context
by: Roberto Ravasio, et al.
Published: (2019-05-01)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021-07-01)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
by: Sanjiv Kapoor, et al.
Published: (2019-06-01)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
by: Vandana Midha, et al.
Published: (2018-01-01)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
by: Hong Zhang, et al.
Published: (2021-04-01)

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
by: Stefan Schreiber, et al.
Published: (2020-06-01)

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
by: Giammarco Mocci, et al.
Published: (2022-07-01)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
by: Roy M. Fleischmann, et al.
Published: (2018-08-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
by: Roy M. Fleischmann, et al.
Published: (2021-09-01)

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

Case report: Area of focus of management of severe pityriasis rubra pilaris by dose optimization of adalimumab biosimilar in combination with acitretin and montelukast
by: Kristine Heidemeyer, et al.
Published: (2023-11-01)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
by: Hong Zhang, et al.
Published: (2021-03-01)

Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
by: Qiyou Wu, et al.
Published: (2023-01-01)

Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
by: William D. Renton, et al.
Published: (2019-10-01)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
by: Claudiu Costinel Popescu, et al.
Published: (2022-12-01)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
by: Marta Vernero, et al.
Published: (2023-10-01)

Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
by: Rianne Brouwer, et al.
Published: (2022-12-01)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
by: Waller J, et al.
Published: (2017-03-01)

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
by: Ahmadreza Jamshidi, et al.
Published: (2017-07-01)

Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants
by: Takuma Yonemura, et al.
Published: (2022-01-01)

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
by: Jonathan Kay, et al.
Published: (2021-02-01)

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
by: Ali M. Alsamil, et al.
Published: (2021-02-01)

Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers
by: Eva Dokoupilová, et al.
Published: (2024-06-01)

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
by: Megna M, et al.
Published: (2022-07-01)

Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries
by: Peter C. Taylor, et al.
Published: (2023-01-01)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
by: Hans C. Ebbers, et al.
Published: (2019-08-01)

Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting
by: Giulia Odorici, et al.
Published: (2022-05-01)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
by: Fang Wang, et al.
Published: (2023-10-01)

Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective
by: Maria Kamusheva, et al.
Published: (2021-01-01)

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason
by: Giammarco Mocci, et al.
Published: (2023-10-01)

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
by: Mark C. Genovese, et al.
Published: (2019-12-01)

Don't be a nocebo! Why healthcare organizations should value patients' expectations
by: David Poulter, et al.
Published: (2024-04-01)